检索结果-南通市图书馆

Science Bulletin 2021年第24期66卷 2445-2447页

作者： norbert claude gorin Department of Hematology and Cell Therapy Hopital Saint Antoine and Paris Sorbonne UniversityParis 75012France

Hematopoeitic stem cell transplantation(HSCT)using a haploidentical family donor(HAPLO)was long thought to be non-feasible,essentially because of HLA incompatibility leading to graft rejection,severe acute(aGVH)and chronic(cGVH)graft versus host disease(GVH),severe infections and unacceptable nonrelapse mortality(NRM).The group in Perugia in the last decade of the past century[1],was the first to be successful by initiating a positive selection of CD34+cells from peripheral blood stem cell(PBSC)collections,providing T cell depleted grafts with very high doses of CD34+cells to be *** combined with intensive conditioning regimen and profound immunosuppression,the Perugia group obtained the first demonstration of feasibility and *** later improved their results in acute myeloid leukemia(AML)by showing that a mismatch for natural killer(NK)cells in the killer-cell immunoglobulin-like receptor(KIR)-human leukocyte-antigen class I(HLA1)donor to recipient direction[2]decreased considerably the relapse incidence(RI).Unfortunately this approach was associated with severe infections,a high NRM and in addition was cumbersome and difficult to reproduce in other non-expert centers.

关键词：造血干细胞移植 acute doses

A vision for the future of allogeneic hematopoietic stem cell transplantation in the next decade

在线全文

学校读者我要写书评

暂无评论

Science Bulletin 2022年第19期67卷 1921-1924页

作者： Meng Lv norbert claude gorin Xiao-Jun Huang Peking University People’s Hospital Peking University Institute of HematologyNational Clinical Research Center for Hematologic DiseaseBeijing Key Laboratory of Hematopoietic Stem Cell TransplantationBeijing 100044China Department of Hematology and Cell Therapy European Society for Blood and Marrow Transplantation Global CommitteeHôpital Saint-Antoine AP-HPParis Sorbonne UniversityParis 75012France Peking-Tsinghua Center for Life Sciences Beijing 100871China

The whole field of hematological malignancies has experienced a huge breakthrough during the past 40 *** methodological progress in cytogenetics(e.g.,fluorescence in situ hybridization,FISH),immunophenotyping(e.g.,multicolor flow cytometers),and molecular biology(with the discovery of numerous tumor molecular markers by polymerase chain reaction and,more recently,next-generation sequencing)has paved the way for the new concept of detecting and monitoring undetectable minimal residual disease(uMRD)and the engineering of multiple new targeted therapies,such as tyrosine kinase inhibitors and various immunotherapies,including monoclonal antibodies combined or not with antitumor agents,bispecific T-cell-engaging(BiTE)antibodies and chimeric antigen receptor T(CAR-T)cells(Supplementary Text 1 online).

关键词： antibodies monoclonal breakthrough

从单核细胞分化的树突状细胞的低温保存及其临床应用(英文)

在线全文

学校读者我要写书评

暂无评论

中国实验血液学杂志 2000年第4期8卷 245-250页

作者： VERG Véronique MARTINACHE Chantal LEON Anne gorin norbert-claude BERNARD Jacky LOPEZ Manuel INSERM U76 Laboratoire de Therapie Cellulaire et de Radioprotection Accidentelle Paris et Fontenay Aux RosesETS AP-HP Site Saint AntoineETS AP-HP Site Saint AntoineINSERM U76 Laboratoire de Therapie Cellulaire et de Radioprotection Accidentelle Paris et Fontenay Aux RosesCentre Jean Godinot ReimsINSERM U76 Laboratoire de Therapie Cellulaire et de Radioprotection Accidentelle Paris et Fontenay Aux Roses Paris FranceParis FranceParis FranceParis FranceParis FranceParis France

树突状细胞 (dendriticcells,DCs)作为专职的抗原递呈细胞 ,已被广泛地应用于临床的肿瘤疫苗治疗。目前的临床方案大多为分次给病人注射 >10 6 个细胞 /次 ,不同批次培养的DCs,连续 4 - 6周。为了提高疗效 ,简化治疗程序及规范疗程 ,有... 详细信息

树突状细胞 (dendriticcells,DCs)作为专职的抗原递呈细胞 ,已被广泛地应用于临床的肿瘤疫苗治疗。目前的临床方案大多为分次给病人注射 >10 6 个细胞 /次 ,不同批次培养的DCs,连续 4 - 6周。为了提高疗效 ,简化治疗程序及规范疗程 ,有必要将DCs低温保存 ,使患者在治疗过程中得到同批次的培养的DCs。本实验从患者外周血采取单个核细胞 ,经细胞淘洗分离单核细胞 ,在 80 0U/mlGM CSF + 10 0ng/mlIL 13的培养条件下 ,将单核细胞于Teflon疏水袋中诱导产生DCs。将DCs以 - 1℃梯度降温及不控温两种方式将DCs冻存于 - 80℃及液氮中。 1个月后 ,4 2℃快速复温。检测其免疫表型 (CD1a ,CD14,CD4 0 ,CD80 ,CD83,CD86,CD5 4 ,CD5 8,CD16,CD32 ,CD64,HLA DR)及其对自体及异体淋巴细胞的刺激作用。结果表明 ,2种方式的低温保存及复温过程不改变DCs的免疫表型及对淋巴细胞的刺激功能。结论 :应用Teflon袋 ,能够从外周血单核细胞中诱导出大批量的DCs ,这些DCs可被低温保存而不改变其功能。

关键词：树突状细胞单核细胞低温保存免疫疗法

源于近端股骨间充质干细胞免疫抑制作用的研究

在线全文

学校读者我要写书评

暂无评论

中华医学杂志 2005年第39期85卷 2780-2784页

作者：张翼鷟 Loic Fouillard Alain Chapel Morad Bensidhoum Christelle Mazurier Aish Nasef Sandrine Bouchet Manuel Lopez Dominique Thierry norbert Cclaucle gorin 达万明解放军总医院血液科 Faculte de Medecine SaintAntoine Universite VIParis75012France

目的探讨源于成人近端股骨的间充质干细胞(MSC)是否具有免疫抑制功能,为临床移植物抗宿主病的防治寻找理想的细胞储备库。方法从全髋关节置换术患者的近端股骨中分离并培养MSC,将不同数量的细胞直接或以Transwell法加入混合淋巴细胞反应... 详细信息

目的探讨源于成人近端股骨的间充质干细胞(MSC)是否具有免疫抑制功能,为临床移植物抗宿主病的防治寻找理想的细胞储备库。方法从全髋关节置换术患者的近端股骨中分离并培养MSC,将不同数量的细胞直接或以Transwell法加入混合淋巴细胞反应(MLR)中,检测MSC对外周血淋巴细胞(PBL)增殖水平的影响。以ELISA法及抗体中和法探讨细胞因子TGFβ1在MSC免疫调节中的作用。结果3×103、1×104、3×104、1×105个源于近端股骨的MSC对PBL增殖的抑制率分别为62%±18%、38%±4%、31%±16%、28%±12%,与采自髂骨骨髓穿刺物MSC的抑制作用相比差异无统计学意义(均P>0.05),后者对PBL的增殖抑制率为58%±12%、37%±8%、28%±6%、27%±6%;以0.2μm的微孔膜对MSC与MLR进行分隔,3×104及1×104个MSC对PBL的增殖抑制率为36%±8%和53%±12%;在ELISA实验中,MSC单独培养,MSC与MLR直接接触,或经Transwell共培养的这3种上清中转化生长因子(TGF)β1的表达水平差异无统计学意义,加入浓度递增的TGFβ1抗体不能逆转MSC对PBL增殖的抑制作用。结论源于近端股骨的MSC具有一定的免疫抑制功能,除TGFβ1外其他可溶性因子可能介导这一作用。

关键词：干细胞股骨免疫抑制淋巴细胞培养试验,混合